menu toggle

Q&A – How the tendency towards decentralized supply chains has changed in CGT

By Jennifer Fenwick

Jennifer Fenwick, Senior Manager, Personalized Supply Chain, joins Dr Matthew Lakelin, Vice President, Scientific Affairs and Product Development at TrakCel, for a Q&A about decentralized supply chains.
Decentralized clinical trials for CGTs
They delve into the reasons why therapy developers should consider investing in an integrated, digital supply chain for CGT, and why finding the right partners will be critical to their digital infrastructure success. 

Contact us

Connect with with our cell and gene therapy experts today. We look forward to hearing from you. 

About The Author

Jennifer Fenwick
Senior Manager, Personalized Supply Chain
World Courier
View Bio